Can COVID-19 have a clinically significant effect on drug metabolism?

Ceban, Felicia; Subramaniapillai, Mehala; Rosenblat, Joshua D; Mansur, Rodrigo B; McIntyre, Roger S

Ceban, Felicia; Subramaniapillai, Mehala; Rosenblat, Joshua D; Mansur, Rodrigo B; McIntyre, Roger S.

Afiliación

Ceban F; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Subramaniapillai M; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Rosenblat JD; Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
Mansur RB; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
McIntyre RS; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.

Expert Opin Drug Saf ; 22(1): 1-3, 2023 01.

Article en En | MEDLINE | ID: mdl-36691834

Asunto(s)

COVID-19; Humanos; Vacunación

Palabras clave

Bipolar disorder; COVID-19; CYP450; SARS-CoV-2; cognition; cytokines; depression; drug metabolism; inflammation; liver; long COVID; mood disorders; pharmacokinetics; pharmacology; pharmacovigilance; population health; post-COVID-19 condition; prevention; tolerability; treatment; vaccination

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google